Brief: GT Biopharma Gets FDA IND Clearance For GTB-5550 TRiKE, B7-H3-Targeted NK Engager For B7-H3+ Solid Tumors
03/02/2026 13:47
Feb 3 (Reuters) - GT Biopharma Inc GTBP.O: GT BIOPHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR GTB-5550 TRIKE®, A B7-H3-TARGETED NATURAL KILLER (NK) CELL ENGAGER FOR SOLID TUMORS EXPRESSING B7-H3 GT BIOPHARMA INC - GTB-5550 PHASE 1 TRIAL TO START MID-2026 Source text: ID:nGNX2zlPxM Further company coverage: GTBP.O ((Reuters.Briefs@thomsonreuters.com;))